We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Assessment of Adverse Events Following COVID-19 Vaccination: A Cross-sectional Study in Ibadan, Nigeria.
- Authors
Alao, Michael Abel; Ogunbosi, Babatunde Oluwatosin; Ibrahim, Olayinka Rasheed; Oladokun, Regina Eziuka; Lagunju, Ikeoluwa Abiola
- Abstract
Background: Vaccination has been described as the most critical tool to end the COVID-19 pandemic and to save lives and livelihoods. This study aimed to evaluate the spectrum of adverse events following immunization with the COVID-19 AstraZeneca/Oxford vaccine in Ibadan, south western Nigeria. Methodology: A cross-sectional study. Adults aged > 18 years who had received the Astra-Zeneca/Oxford COVID-19 vaccine at selected COVID-19 vaccination centres across three Local Government Areas in Ibadan, SW Nigeria were interviewed by means of a structured questionnaire to determine the spectrum of adverse events following immunisation (AEFI). Results: We enrolled 369 adults; 179 males and 190 females, with a mean of age of 37.8 ± 12.0 years. Three hundred and thirty two (90.0%) of the subjects experienced one or more AEFI. Of the total AEFIs reported, the most frequent were headache 225 (21.1%), fatigue/tiredness 186 (17.4%), pain at the injection site 99 (9.3%) and myalgia 97(9.1%). Nine in ten (96.4%) of these AEFIs occurred within 48 hours postvaccination. Higher severity of adverse events score (p=0.049) and multiple AEFIs (p=0.01) were associated with the first dose of the vaccine. There were severe AEFI in 1.2 % (95% CI: 0.3-.9.0%) of the respondents. Presumed or confirmed COVID 19 infection before vaccination increased the odds of AEFI (OR 7.0,95% CI: 1.8-27.8). Conclusion: Our study showed a high frequency of AEFI among recipients of the Astra Zenecca/Oxford vaccine in Ibadan. Majority of the AEFIs are mild and self-limiting.Previous infection with COVID-19 appears to increase the risk of AEFI.
- Subjects
IBADAN (Nigeria); NIGERIA; UNIVERSITY of Oxford; ASTRAZENECA PLC; SARS-CoV-2; COVID-19 vaccines; COVID-19; CROSS-sectional method
- Publication
Nigerian Medical Journal, 2022, Vol 63, Issue 3, p248
- ISSN
0300-1652
- Publication type
Article